Geron Corp (GERN) Stock Price & Analysis
Geron Corp (GERN) fell 2.07% to USD 1.42 as of July 25, 2026 at 07:43 UTC, according to Nexqual real-time market data.
GERN last closed at USD 1.45; the session ranged USD 1.41–1.46 on volume of 3,290,531 shares. Market capitalization is $910.96M, with a 52-week range of USD 1.04–2.01 (NMS). Source: Nexqual, July 25, 2026 at 07:43 UTC.
Key Statistics (as of July 25, 2026 at 07:43 UTC)
| Price | USD 1.42 |
|---|---|
| Change | ▼ 2.07% (down) |
| Previous Close | USD 1.45 |
| Open | USD 1.45 |
| Day Range | USD 1.41 – 1.46 |
| 52-Week Range | USD 1.04 – 2.01 |
| Volume | 3,290,531 shares |
| Market Cap | $910.96M |
| Exchange | NMS |
Technical Analysis (GERN)
Nexqual's technical model rates GERN "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 07:43 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.22 (neutral) |
| vs SMA50 | Above (USD 1.31) |
| MACD | 0.03 (positive) |
Analyst Ratings (GERN)
Wall Street analysts rate GERN "Buy" based on 4 analysts, with a mean price target of USD 4 (range USD 3–5), per Nexqual as of July 25, 2026 at 07:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 4 |
| High Target | USD 5 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (GERN)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.01 |
| Revenue Estimate | $55.38M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0 vs est -0.02 ▲ beat |
| 2025-12-31 | USD -0.02 vs est -0.05 ▲ beat |
| 2025-09-30 | USD -0.03 vs est -0.04 ▲ beat |
| 2025-06-30 | USD -0.02 vs est -0.03 ▲ beat |
Source: Nexqual, July 25, 2026 at 07:43 UTC.
Financials & Fundamentals (GERN)
| Total Revenue | $196.12M |
|---|---|
| Revenue Growth (YoY) | +30.90% |
| Gross Margin | +60.97% |
| Operating Margin | -0.46% |
| Profit Margin | -34.32% |
| ROE | -27.07% |
| Debt / Equity | 53.28 |
| Current Ratio | 6.78 |
| Total Cash | $312.40M |
| Total Debt | $122.07M |
| Free Cash Flow | $-92.14M |
Source: Nexqual, July 25, 2026 at 07:43 UTC.
Financial Health Score (GERN)
Nexqual rates Geron Corp's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 07:43 UTC.
| Growth | Strong — Revenue +139% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 61%, operating -0% |
| Balance Sheet | Strong — $312M cash vs $122M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$92M, burning cash |
| Efficiency | Critical — ROE -27%, ROA -4.0% |
Ownership (GERN)
| Insider Ownership | +0.08% |
|---|---|
| Institutional Ownership | +79.92% |
| Shares Outstanding | 641.52M |
| Float | 535.70M |
| Short % of Float | +10.91% |
Source: Nexqual, July 25, 2026 at 07:43 UTC.
Leadership (GERN)
Geron Corp is led by Harout Semerjian (age 55), CEO, President & Director, per Nexqual as of July 25, 2026 at 07:43 UTC.
| CEO, President & Director | Harout Semerjian (age 55) |
|---|---|
| EVP, CFO, Treasurer and Principal Financial & Accounting Officer | Michelle J. Robertson (age 58) |
| Senior Vice President of Investor Relations & Corporate Affairs | Dawn Schottlandt |
| Vice President of Investor Relations & Corporate Communications | Aron Feingold |
Major Backers & Investors (GERN)
Notable institutional backers of Geron Corp include RA Capital Management, L.P., Soleus Capital Management, L.P., Deep Track Capital, Lp, according to Nexqual as of July 25, 2026 at 07:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 9.94% |
| Soleus Capital Management, L.P. | 6.47% |
| Deep Track Capital, Lp | 4.94% |
| Citadel | 3.36% |
| Point72 Asset Management, L.P. | 3.19% |
| ClearBridge Investments, LLC | 3.06% |
| Eversept Partners, LP | 2.94% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.8% |
| Vanguard Group | 9.81% |
| State Street | 8.14% |
Source: Nexqual, July 25, 2026 at 07:43 UTC.
From Geron Corp's Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe that the results of our Phase 3 clinical trial, IMerge, in LR-MDS, favorable FDA label and National Comprehensive Cancer Network, or NCCN®, Clinical Practice Guidelines in Oncology, or NCCN Guidelines®, position RYTELO as a potential treatment that can compete for significant market segments in lower-risk MDS, including second-line ESA ineligible patients regardless of prior treatment or RS status and first-line ESA ineligible patients.
- Imetelstat, our proprietary telomerase inhibitor which was discovered and developed at Geron, was designed to inhibit telomerase in malignant cells with continuously upregulated telomerase.
Partnerships
- To enable paid access to patients outside the United States through approved Named Patient Programs (NPPs), we have partnered with Tanner Pharma, a distributor with broad global reach to support patient access.
- In accordance with the termination provisions of the Prior Collaboration Agreement, we have an exclusive worldwide license for intellectual property developed under the Prior Collaboration Agreement for the further development, commercialization and marketing of imetelstat, without any economic obligations to Janssen with respect to such license.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STEM | Stem, Inc. | USD 5.49 | ▼ 8.65% |
| AGEN | Agenus Inc. | USD 5.98 | ▲ 8.14% |
| EXEL | Exelixis, Inc. | USD 55.37 | ▲ 0.71% |
| INCY | Incyte Corporation | USD 117.67 | ▲ 1.62% |
| BCRX | BioCryst Pharmaceuticals, Inc. | USD 9.34 | ▼ 1.79% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:43 UTC. This page is informational and not investment advice.